Comment on: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”

Clinical Pharmacokinetics

Volumn 54, Issue 12, 2015, Pages 1293-1295

  Srinivas, Nuggehally R ^a  

^a Suramus Biopharm   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FILGOTINIB; ANTIRHEUMATIC AGENT; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INHIBITORY CONCENTRATION; LETTER; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; ARTHRITIS, RHEUMATOID; MALE; METABOLISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MALE; PYRIDINES; TRIAZOLES;

EID: 84948568321     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0335-6     Document Type: Letter

References (8)

1. O’Shea JJ, Kontzias A, Yamaoko K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl. 2):111–5.
2. Ghoreschi K, Jesson M, Li X, Lee J, Ghosh S, Alsup J, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.
3. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513–26.
4. Haan C, Rolvering C, Raulf F, Kapp M, Druckes P, Thoma G, et al. Jak1 has a dominant role over Jak3 in signal transduction through cc containing cytokine receptors. Chem Biol. 2011;18:314–23.
5. Van Rompaey L, Galien R, Van der Aar E, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1 for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568–77.
6. Galien R, Vayssière B, De Vos S, Auberval M, Vandeghinste N, Dupont S, et al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy subjects and rheumatoid arthritis patients [abstract no. 478]. San Diego: American College of Rheumatology Annual Meeting; 36–30 Oct 2013.
7. Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–74.
8. Vanhoutte F, Mazur M, Der Van, Aa A, Wigerinck P, Van’t Klooster G. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634 [abstract]. Arthritis Rheum. 2012;64(Suppl. 10):2489.